Edition:
United States

OncoSec Medical Inc (ONCS.OQ)

ONCS.OQ on NASDAQ Stock Exchange Capital Market

1.52USD
4:00pm EDT
Change (% chg)

$-0.06 (-3.80%)
Prev Close
$1.58
Open
$1.58
Day's High
$1.58
Day's Low
$1.51
Volume
71,779
Avg. Vol
92,926
52-wk High
$2.95
52-wk Low
$0.88

Latest Key Developments (Source: Significant Developments)

Oncosec Expands Relationship With Merck For Combination Of Immunopulse Il-12 And Keytruda
Tuesday, 8 May 2018 07:30am EDT 

May 8 (Reuters) - OncoSec Medical Inc ::ONCOSEC EXPANDS RELATIONSHIP WITH MERCK, ANNOUNCES CLINICAL COLLABORATION TO EVALUATE COMBINATION OF IMMUNOPULSE IL-12 AND KEYTRUDA FOR TRIPLE NEGATIVE BREAST CANCER.ONCOSEC MEDICAL - PLANNED TRIAL WILL EVALUATE SAFETY, EFFICACY OF COMBINATION IN CERTAIN PATIENTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC TNBC.ONCOSEC MEDICAL SAYS UNDER COLLABORATION AGREEMENT, ONCOSEC WILL SPONSOR, FUND STUDY AND MERCK WILL PROVIDE KEYTRUDA.ONCOSEC MEDICAL SAYS ADDITIONAL DETAILS OF THE COLLABORATION WERE NOT DISCLOSED.  Full Article

Oncosec Medical Says Board Determined To Consolidate Roles Of CEO And President
Friday, 4 May 2018 04:05pm EDT 

May 4 (Reuters) - OncoSec Medical Inc ::ONCOSEC MEDICAL INC - BOARD DETERMINED TO CONSOLIDATE ROLES OF CHIEF EXECUTIVE OFFICER AND PRESIDENT.ONCOSEC MEDICAL INC - PUNIT DHILLON WILL NO LONGER SERVE AS PRESIDENT OF COMPANY, BUT WILL REMAIN AS A MEMBER OF BOARD OF DIRECTORS.ONCOSEC MEDICAL INC - DANIEL CONNOR TO SERVE AS BOTH CHIEF EXECUTIVE OFFICER AND PRESIDENT - SEC FILING.  Full Article

Oncosec Medical Prices $20 Mln Public Offering Of Common Stock
Thursday, 1 Feb 2018 09:21am EST 

Feb 1 (Reuters) - Oncosec Medical Inc ::PRICES $20.0 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 13.3 MILLION COMMON SHARES PRICED AT $1.50PER SHARE.  Full Article

Oncosec Plans To Conduct A Second Clinical Trial In Triple Negative Breast Cancer In 2018​
Wednesday, 3 Jan 2018 08:00am EST 

Jan 3 (Reuters) - Oncosec Medical Inc ::ONCOSEC PROVIDES 2018 BUSINESS OUTLOOK.ONCOSEC MEDICAL INC - PLAN TO CONDUCT A SECOND CLINICAL TRIAL IN TRIPLE NEGATIVE BREAST CANCER IN 2018​.ONCOSEC MEDICAL -‍PLAN TO CONDUCT 2 INVESTIGATOR SPONSORED TRIALS IN SQUAMOUS CELL CARCINOMA OF HEAD, NECK AND IN MELANOMA NEOADJUVANT SETTING IN 2018​.ONCOSEC MEDICAL INC - PREPARE TO COMMERCIALLY LAUNCH IMMUOPULSE IL-12 IN U.S. IN 2018.  Full Article

Oncosec Announces Dosing Of First Patient In Registration-Directed Phase 2B Clinical Trial
Thursday, 14 Dec 2017 08:00am EST 

Dec 14 (Reuters) - Oncosec Medical Inc ::ONCOSEC ANNOUNCES DOSING OF FIRST PATIENT IN REGISTRATION-DIRECTED PHASE 2B CLINICAL TRIAL, PISCES/KEYNOTE-695, OF IMMUNOPULSE® IL-12 IN COMBINATION WITH PEMBROLIZUMAB.  Full Article

OncoSec Medical files for offering of up to 6.83 mln shares
Thursday, 16 Nov 2017 08:59am EST 

Nov 16 (Reuters) - Oncosec Medical Inc -:OncoSec Medical Inc files for offering of up to 6.83 million shares of co's common stock by the selling shareholders - SEC filing.  Full Article

Oncosec announces positive follow-up data from phase 2 trial of Immunopulse il-12
Wednesday, 8 Nov 2017 07:30am EST 

Nov 8 (Reuters) - Oncosec Medical Inc :Oncosec announces positive updated long-term follow-up data from phase 2 trial of Immunopulse il-12 in combination with pembrolizumab demonstrating a progression free survival rate (PFS) of 57% at 15 months in predicted anti-pd-1 non-responder melanoma p.  Full Article

Oncosec appoints Daniel O'Connor as CEO
Tuesday, 7 Nov 2017 05:04pm EST 

Nov 7 (Reuters) - Oncosec Medical Inc :Oncosec appoints Daniel J. O'Connor as chief executive officer to lead next stage of growth as a fully integrated late stage development and commercial company.Oncosec medical - ‍punit Dhillon, co-founder of Oncosec, will continue to serve as company's president and a member of its board​.  Full Article

Intracoastal Capital LLC reports 7.5 pct passive stake in OncoSec Medical
Tuesday, 31 Oct 2017 05:00pm EDT 

Oct 31 (Reuters) - OncoSec Medical Inc :Intracoastal Capital LLC reports 7.5 pct passive stake in OncoSec Medical Inc, as of October 22, 2017‍​.  Full Article

OncoSec Q4 loss per share $0.28
Wednesday, 25 Oct 2017 04:15pm EDT 

Oct 25 (Reuters) - OncoSec Medical Inc : :OncoSec announces fourth quarter and year end financial results for fiscal year 2017.Q4 loss per share $0.28.OncoSec medical - ‍expects current funds to be sufficient to allow co to continue to operate business to third calendar quarter of 2018​.  Full Article

BRIEF-Oncosec Expands Relationship With Merck For Combination Of Immunopulse Il-12 And Keytruda

* ONCOSEC EXPANDS RELATIONSHIP WITH MERCK, ANNOUNCES CLINICAL COLLABORATION TO EVALUATE COMBINATION OF IMMUNOPULSE IL-12 AND KEYTRUDA FOR TRIPLE NEGATIVE BREAST CANCER